Source - LSE Regulatory
RNS Number : 1981A
Futura Medical PLC
17 January 2020


17 January 2020

Result of General Meeting, Issue of Equity, Admission and Total Voting Rights

Futura Medical plc (AIM: FUM) (the "Company"), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal Dermasys® drug delivery technology and focused on sexual health and pain, announces that, at its General Meeting held earlier today, all resolutions were duly passed by the shareholders.

Application has been made to the London Stock Exchange for 40,625,000 Ordinary Shares to be admitted to trading on AIM. It is expected that Admission will be effective and trading will commence at 8.00 a.m. on 20 January 2020.

Following Admission, the Company will have 245,285,267 Ordinary Shares in issue. As the Company currently holds no shares in treasury, the total number of voting rights in the Company is therefore 245,285,267 and this figure may therefore be used by Shareholders. 

Terms in this announcement have the meaning given to them in the Circular issued in connection with the Fundraising and the announcement released on 20 December 2019 with the RNS Number 7183X. 

For further information please contact:

Futura Medical plc 
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO

Tel: +44 (0) 1483 685 670


Nominated Adviser and Sole Broker:
Bidhi Bhoma/ Euan Brown/ Kane Collings
Tel: +44 (0) 20 3100 2000


For media enquiries please contact:

Optimum Strategic Communications

Mary Clark/ Eva Haas/ Hollie Vile


Tel: +44 (0) 203 950 9144



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.